152 results on '"Degos, Laurent"'
Search Results
2. History of Acute Promyelocytic Leukemia
3. Axel, le solitaire
4. Predictive factors of diagnostic and therapeutic divergence in a nationwide cohort of patients seeking second medical opinion
5. Overcoming fragmentation of health research in Europe: lessons from COVID-19
6. Differentiation Therapy of Acute Promyelocytic Leukemia
7. Retinoids in Oncology: Conclusions and Future Directions
8. Clinical and Molecular Advances in Acute Promyelocytic Leukaemia
9. Introduction
10. ATRA Therapy in Acute Promyelocytic Leukemia a Model for Differentiation Therapy
11. All trans retinoic acid as a targeting drug for differentiation therapy in acute promyelocytic leukemia
12. Quelles valeurs pour quelle politique de santé ?
13. Notre système de santé, mal dans sa peau ?
14. Complémentarité entre médecine traditionnelle chinoise (MTC) et médecine occidentale
15. Conclusion de la séance dédiée : « La leucémie myéloïde chronique »
16. Bernard Guiraud Chaumeil. Ils ont inventé la médecine, gardons-lui son humanité. Éditions Michel Lafon, 2016
17. Scientific Panel for Health: better research for better health
18. Le pouvoir des sociétés savantes
19. Complémentarité entre Médecine Traditionnelle Chinoise (MTC) et Médecine Occidentale
20. Change in the Fine Specificity of a Human Cytotoxic T Cell Clone Under α-Interferon Treatment
21. Sendai Virus Infection of Tumor Cells Increases the Production of Autoreactive H-2 Specific Antibodies in Syngeneic Recipients
22. Involvement of the H-2 Complex in Steroid Hormone Metabolism
23. Immunization with Fibroblasts Expressing Human β 2-Microglobulin Induces H-2 Specific Antibodies in Syngeneic Recipients
24. Structural Mapping of T Cell Clones Restriction Elements Suggests That a DQα-DRβ Hybrid Molecule Could Be Functional in DRw13 Cells
25. Molecular Cloning of an Inducible Cytotoxic T-Lymphocyte-Associated Gene (Hu-CTLA 1) and Gene Localization to Human Chromosome 14
26. Studies of HLA-DR Antigens by Complement Fixation
27. In Vitro Differentiation of a Human Thymic Clone Coexpressing CD4 and CD8 Molecules
28. DR and DQ a and ß Polymorphism in DRw13- and DRw52 +-Related Haplotypes
29. Clinical Investigation of Lithium Therapy in Acute Leukemia
30. Immunization with Fibroblasts Transfected with a Cloned Retroviral DNA Induces H-2 Specific Antibodies in Syngeneic Recipients
31. HLA-Bw35 Antigen, Mitral Valve Prolapse and Blood Magnesium Level
32. All-Trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
33. N’oublions Pas Demain
34. Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials
35. Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL– Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group
36. Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts)
37. Adverse events in medicine: Easy to count, complicated to understand, and complex to prevent
38. Two faces of patient safety and care quality: a Franco-American comparison
39. IMPROVEMENT OF BASI TREATMENT PRESCRIBED AT DISCHARGE FOR MI PATIENTS: RESULTS OF THE FRENCH NATIONAL PERFORMANCE MEASURE ASSESSMENT
40. Check-list « Sécurité du patient au bloc opératoire »
41. Do Early Events Excluding Patients with Acute Promyelocytic Leukemia (APL) From Trial Enrollment Modify Treatment Result Evaluation? Real-Life Management of 100 Patients Referred to the University Hospital Saint-Louis Between 2000 and 2010.
42. Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases
43. Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group
44. Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group
45. Gérer les conflits d’intérêts pour plus de confiance
46. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
47. Suitability of three indicators measuring the quality of coordination within hospitals
48. Hommage à Jean Dausset
49. Relative effectiveness assessment of listed drugs (REAL): A new method for an early comparison of the effectiveness of approved health technologies
50. Very Long Term Outcome of Acute Promyelocytic Leukemia After Treatment with All Trans Retinoic Acid and Chemotherapy: The European APL Group Experience.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.